Compare PANL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | IPSC |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.5M | 441.9M |
| IPO Year | 2015 | 2021 |
| Metric | PANL | IPSC |
|---|---|---|
| Price | $7.04 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $4.25 |
| AVG Volume (30 Days) | 536.9K | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $385,088,209.00 | $109,164,000.00 |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $4.46 | $0.44 |
| 52 Week High | $9.39 | $2.97 |
| Indicator | PANL | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 50.26 |
| Support Level | $6.54 | $2.14 |
| Resistance Level | $7.35 | $2.53 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 63.24 | 44.68 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.